Company news

Cytokinetics, Incorporated news in 2023

Cytokinetics, Incorporated's news releases, calls and decks from 2023, newest first.

View company

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

December 26, 2023

Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

December 25, 2023

Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND

December 6, 2023

Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND

November 28, 2023

Cytokinetics Reports Third Quarter 2023 Financial Results

November 1, 2023

Cytokinetics to Participate in Upcoming Investor Conferences

October 31, 2023

Cytokinetics to Announce Third Quarter Results on November 2, 2023

October 22, 2023

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

October 18, 2023

Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

October 5, 2023

Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023

October 4, 2023

Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

October 1, 2023

Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program

September 27, 2023

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

September 5, 2023

Cytokinetics Reports Second Quarter 2023 Financial Results

August 2, 2023

Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

July 31, 2023

Cytokinetics to Announce Second Quarter Results on August 3, 2023

July 26, 2023

Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

June 19, 2023

Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress

May 19, 2023

Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress

May 14, 2023

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586

May 10, 2023

Cytokinetics to Participate in the JMP Securities Life Sciences Conference

May 7, 2023

Cytokinetics Reports First Quarter 2023 Financial Results

May 3, 2023

Cytokinetics to Announce First Quarter Results on May 4, 2023

April 19, 2023

Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference

April 9, 2023

Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis

March 30, 2023

Cytokinetics Releases Inaugural Corporate Responsibility Report

March 26, 2023

Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session

March 3, 2023

Cytokinetics Reports Fourth Quarter 2022 Financial Results

February 28, 2023

Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil

February 27, 2023

Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session

February 23, 2023

Cytokinetics to Announce Fourth Quarter Results on March 1, 2023

February 14, 2023

Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program

January 29, 2023

Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Calls in 2023

Decks in 2023